Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATIC | P31939 | 3/20 | 1.00 |
| ▸ | FBP1 | P09467 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LDHA | P00338 | 2/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.61 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.61 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.61 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.61 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1230585 | 1.00 | ATIC (1.00) | ATICFBP1KDM4ETDP1TP53 | |
| SCHEMBL1230589 | 1.00 | ATIC (1.00) | ATICFBP1KDM4ETDP1TP53 | |
| SCHEMBL849848 | 1.00 | ATIC (1.00) | ATICFBP1KDM4ETDP1TP53 | |
| SCHEMBL4359472 | 1.00 | ATIC (1.00) | ATICFBP1KDM4ETDP1TP53 | |
| SCHEMBL20276955 | 1.00 | ATIC (1.00) | ATICFBP1KDM4ETDP1TP53 | |
| SCHEMBL15520399 | 1.00 | ATIC (1.00) | ATICFBP1KDM4ETDP1TP53 | |
| SCHEMBL20277605 | 0.91 | ATIC (0.84) | ATICFBP1KDM4ETDP1TP53 | |
| SCHEMBL24024836 | 0.91 | ATIC (0.84) | ATICFBP1KDM4ETDP1TP53 | |
| SCHEMBL4359558 | 0.91 | ATIC (0.84) | ATICFBP1KDM4ETDP1TP53 | |
| SCHEMBL850149 | 0.91 | ATIC (0.84) | ATICFBP1KDM4ETDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185100-B2 | Methods for modulating taste receptors | MARS, INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200405736-A1 | TARGETING NAD+ TO TREAT CHEMOTHERAPY AND RADIOTHERAPY INDUCED COGNITIVE IMPAIRMENT, NEUROPATHIES AND INACTIVITY | METRO INTERNATIONAL BIOTECH, LLC | 2020-12-31 | — | — | US | disclosed |
| US-20190021380-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180168208-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180125871-A1 | Targeting NAD+ to Treat Chemotherapy and Radiotherapy Induced Cognitive Impairment, Neuropathies and Inactivity | METRO INTERNATIONAL BIOTECH, LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405736-A1 | TARGETING NAD+ TO TREAT CHEMOTHERAPY AND RADIOTHERAPY INDUCED COGNITIVE IMPAIRMENT, NEUROPATHIES AND INACTIVITY | NQO1, SIRT1, NNMT | ATIC 2725/4885FBP1 819/4885KDM4E 3704/4885 |
| US-20180125871-A1 | Targeting NAD+ to Treat Chemotherapy and Radiotherapy Induced Cognitive Impairment, Neuropathies and Inactivity | NQO1, SIRT1, NNMT | ATIC 2725/4885FBP1 819/4885KDM4E 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.